



Marksans Pharma Ltd.

# Investor Presentation

Q1 FY21

4<sup>th</sup> August 2020

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026

©2019 – Marksans Pharma Limited, All Rights Reserved.



Marksans Pharma Ltd.

## Safe Harbor

Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.

# Q1FY21 Highlights



Marksans Pharma Ltd.

**34.0%**

(YoY)



**Revenue**

**102.9%**

(YoY)



**EBITDA**



**Mark Saldanha**


Managing Director And CEO



**119.6%**

(YoY)

**Cash**



**118.1**

₹ crore





As on 'Jun-20

*"I am happy to state that we have achieved another quarter of robust performance, wherein we achieved our highest ever EBITDA of Rs.70.2 crores. This was due to all round growth across geographies. I wish to place on record my gratitude to our employees who have tirelessly worked despite the operational challenges faced from the pandemic. We remain cautiously confident of delivering such superior performance going forward."*

# Operational Excellence leading to positive margin & return ratios



Marksans Pharma Ltd.



Ratios calculated using standardized financial formula

# Agenda

- Q1 FY21 Performance Review
- Operational review and financials
- Company at a glance
- Long-term strategy
- Research & development
- Segmental revenue composition
- Investment rationale



Marksans Pharma Ltd.



# Q1 FY21 Performance Review

# Growth in Profitability



Marksans Pharma Ltd.

In Rs. Cr.	Q1FY21	Q1FY20	YoY Growth (%)	Q4FY20	QoQ Growth (%)
<b>Total Revenue</b>	331.3	247.2	<b>34.0%</b>	335.4	<b>-1.2%</b>
<b>EBITDA</b>	70.2	34.6	<b>102.9%</b>	69.2	<b>1.4%</b>
<b>EBITDA Margin%</b>	<b>21.2%</b>	<b>14.0%</b>	<b>720 bps</b>	<b>20.6%</b>	<b>55 bps</b>
<b>PAT</b>	49.4	22.5	<b>119.6%</b>	42.7	<b>15.5%</b>
<b>PAT Margin%</b>	<b>14.9%</b>	<b>9.1%</b>	<b>580 bps</b>	<b>12.7%</b>	<b>215 bps</b>

## Key Highlights

- Overall business grew by 34.0% in Q1FY21 when compared to Q1FY20
  - Due to strong growth across all the key markets
- EBITDA was Rs. 70.2 cr. as compared to Rs. 34.6 Cr. in Q1FY20, an increase of 102.9%
- PAT stood at Rs. 49.4 cr. as compared to Rs. 22.5 cr. in Q1FY20, a growth of 119.6%

Source – Company Data

# Financials



Marksans Pharma Ltd.

Consolidated (₹ Cr.)	Q1'21	Q4'20	Q1'20	FY'20
Total Revenue	331.3	335.4	247.2	1,134.5
Material Consumption	139.6	147.8	124.3	544.9
<b>Gross Profit</b>	191.6	187.5	120.8	589.3
<i>Gross Margin %</i>	57.9%	55.9%	49.3%	52.0%
Operating Expenses	121.6	118.3	88.3	397.1
<b>EBITDA</b>	70.2	69.2	34.6	192.6
<i>EBITDA Margin %</i>	21.2%	20.6%	14.0%	17.0%
Finance Cost	1.6	2.0	2.3	8.7
Depreciation and amortization	7.2	9.6	4.7	26.7
<b>Earnings Before Tax</b>	61.4	57.6	27.6	157.2
Taxes	12.0	14.8	5.1	36.4
<b>Earnings After Tax</b>	<b>49.4</b>	<b>42.7</b>	<b>22.5</b>	<b>120.8</b>
<i>PAT Margin %</i>	14.9%	12.7%	9.1%	10.6%

\*Gross Profit & Gross Margin is calculated using revenue from operation

Source – Company Data



# Business Review



Marksans Pharma Ltd.

Rs. Cr.	Q1FY21	Q1FY20	YoY Growth (%)	Q4FY20	QoQ Growth (%)	Mix (Q1FY21) %
Europe, UK	144.2	100.9	43.0%	149.1	-3.3%	43.5%
US & North America	133.6	103.6	29.0%	126.5	5.6%	40.3%
Australia & NZ	34.1	30.8	10.8%	47.5	-28.2%	10.3%
Rest of World (ROW)	19.4	12.0	62.2%	12.3	57.9%	5.8%
<b>Consolidated Revenue from operations</b>	<b>331.3</b>	<b>247.2</b>	<b>34.0%</b>	<b>335.4</b>	<b>-1.2%</b>	<b>100.0%</b>

## Key Highlights

**Almost 94% of company's total revenue came from regulated markets of US, Europe, Australia and New Zealand**

- Formulation business from Europe, UK was Rs. 144.2 cr. this fiscal as compared to Rs. 100.9 cr. achieved during same period last year registering a growth of 43.0%
- US & North America reported growth of 29.0% to Rs 133.6 cr. in Q1FY21
- Australia & NZ revenue was at Rs. 34.1 cr. in Q1FY21, registering growth of 10.8% YoY

Source – Company Data




# Operational review and financials

# Consolidated Revenue up 34% in Q1FY21 led by Strong Growth in all Geographies



Marksans Pharma Ltd.



## Topline driven by key geographies

- The revenue growth in Q1FY21 was driven by increasing market share in all the key geographies

## US Region:

- Revenue from the US market grew 29.0% over Q1FY20, contributing to ~40% of the total revenues
- Time Cap Labs Inc has achieved revenue of USD 59.23 Million in FY20 (FY 19-USD 57.91 Million)

## UK Europe:





- Strong product pipeline followed by successful launches every quarter
- In Europe, UK, company targets focused segments where competition is low
- There is a consistency in the top line generation and will be followed by existing pipeline and future launches

Source – Company Data

# EBITDA Margin Increased by 336 bps during FY20 – Strong Growth Expected in FY 21



Marksans Pharma Ltd.



## Steady growth in the profitability

- Gross margin improved from 49.3% during Q1FY20 to 57.9% in Q1FY21 due to better product mix in US, UK and Europe
- Q1FY21 had a 720 bps increase in EBITDA margin compared to Q1FY20. This was the result of enriching product basket with superior products and higher improved operating efficiency across the business
- PAT margins for Q1FY21 was at 14.9%.


Source – Annual Report

# Balance Sheet Trends (Jun 20 vs Mar 20)



Marksans Pharma Ltd.

Particulars (₹ Cr.)	Jun-20	Mar-20
Net Worth	696.3	636.0
Capital Employed	735.3	677.2
Net debt	-93.2	-74.9
Cash & Bank Balance	118.1	93.7
Inventories	260.6	241.8
WC Cycle	131	119
Asset Turnover	1.2x	1.3x



Ratios calculated using standardized financial formula

## Highlights

- The Company's cash balance as on June 2020 is ₹118.1 cr
- Strong ROCE of 27.1%
- Net debt to EBITDA as on June 2020 is -0.41 as company has zero net debt (including long-term and short-term borrowing)

Source – Company Data



Marksans Pharma Ltd.



# Company at a glance

# Company Overview



Marksans Pharma Ltd.

## Business Description

- Marksans Pharma Ltd., headquartered at Mumbai, is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations
- Key focus areas lie in OTC & prescription (Rx) drugs
- Company manufactures tablets (plain, enteric coated and film coated), hard & soft gelatin capsule, oral liquids and ointments
- Its manufacturing facilities are accredited by USFDA, UKMHRA and Australian TGA

## Business Model



- 94% of revenues comes from regulated markets




- Forward-integrated business model




- Presence in niche softgel segment

## Revenue Mix




## Geographic Mix



## Product Portfolio

Rs. Cr.




(FY20)

# Marksans Pharma Evolution



Marksans Pharma Ltd.







## Focus on Regulated Markets

- Marksans commenced business with CRAMS directed at the UK and Australian markets
- Entered the regulated Australian market with the acquisition of Nova in 2005
- Entered the regulated UK market with the acquisition of Bell Sons & Company Ltd. in 2007 and Relonchem Limited in 2008
- Entered the US market in 2011-12 and acquired Time-Cap Laboratories in 2015
- The Company now has a global presence across 25 countries



## Forward integrated business model

- Marksans commenced operations as a formulations manufacturing enterprise
- The Company entered front-end marketing in regulated markets through acquisitions
- The Company was among a few Indian mid-sized companies with frontend marketing capabilities
- The Company invested in a state of- the-art R&D facility, strengthening integration




## Wider product basket

- Marksans commenced its journey with products addressing the pain management segment
- The Company focused on high-growth areas impacted by lifestyle disorders
- The Company launched soft gelatin capsules, a niche category
- The Company now offers products across >10 therapeutic segments

# Company Structure



Marksans Pharma Ltd.



# Manufacturing Capabilities



Marksans Pharma Ltd.

## Goa, India




- Manufactures oral solid tablets and soft gelatin capsules
- One of the biggest manufacturing facility in Asia having 18,000 square mtr campus

### Capacity

- 2.4 bn softgel and hard gelatin capsules per annum
- 5 bn tablets per annum

### Accreditations



## Southport, UK



- Manufactures non-sterile liquids, ointments and powder products
- Supplies to UK, West Africa & Middle East

### Capacity

- 13.6 mn bottles per annum
- 7.8 mn tubes per annum
- 5.7 mn sachets per annum

### Accreditations



## Farmingdale, USA



- Manufactures soft gels, tablets and capsules
- Spread across an area of 7000 sq. m
- "Made in the USA" product offering

### Capacity

- 6 bn tablets and hard capsules per annum

### Accreditations





# Long-term strategy

# Strategic focus on Regulated Markets



Marksans Pharma Ltd.

Marksans Pharma generates ~94% of its revenues from regulated markets



USA



UK



Australia



New Zealand

- Marksans Pharma entered strategic tie-ups and acquired key players in major markets to expand its global footprint
- Company can generate higher margins by eliminating third parties from the value chain
- Currently, the company markets products in 25+ countries with **the UK and the US being the largest**
- Other prominent markets include Australia, New Zealand, Canada and several other European countries
- These markets are empowered with regulatory approvals which allows the company to sell its products without restrictions
- Marksans is among a handful of Indian players with a proprietary marketing presence in the world's largest pharma market such as US, UK and Australia
- The Company expects to expand in the regulated markets through integrated product development, cGMP compliance, regulatory compliance and utilization of latest technologies

# Niche Formulations with few Competitors



Marksans Pharma Ltd.

Marksans Pharma is currently one of the most active Indian firms focused in Softgel segment




- **Differentiated offerings:** Focused on softgel capsules with a view to build a differentiated set of offerings in the crowded generics market
- **Limited competition** - Given the challenges in preparing Softgel formulations plus other economic, technical and patent constraints there are not many players in this segment
- **High barriers to entry** – High capex requirements and operational costs further restrict entry
- **Selectively targeted larger markets:** Marksans has filed softgel products in all major markets including USA, UK, Europe, Canada, Australia & Russia. Of this, US alone is potentially a USD9 billion market
- **New approvals:** 6 new approvals are awaited in US
- **Manufacturing capabilities with regulatory approvals:** Marksans' Goa facility has a capacity to turn out 2.4 billion softgel capsules per annum, and has all the necessary approvals by USFDA, UKMHRA, TGA & other key regulatory authorities

# Forward Integrated Business Model



Marksans Pharma Ltd.



\*Mumbai has only R&D center in Navi Mumbai



# Research & development




# R&D Continues to be the Backbone of the Marksans



Marksans Pharma Ltd.

In FY20, total R&D expenditure was Rs. 8.3 crore



## R&D activities comprises of:

- **Developing** generic products and pharmaceutical formulations
- **Identifying niche areas** (such as cardiovascular diseases, diabetes and neuroscience) for product development
- **Post-patent filing** for regulated and emerging markets
- **Collaborating with partners** in developing drugs going off-patent

## KEY HIGHLIGHTS

- Marksans newly commissioned state of art R&D center apart from the existing Goa facility, at Navi Mumbai fosters its foray into new segments, cater to hitherto unmet globally therapeutic needs and enhance the Company's opportunity responsiveness and to file a larger number of ANDAs
- Team of over **50 experienced scientists** specializing in new drug delivery systems, formulation development and analytical development
- The company continues to maintain regulatory certifications with MHRA, TGA and USFDA, based on recent inspections
- **Marksans's ability to formulate and market a drug in the shortest possible lead time has given the business a critical competitive advantage**




# Segmental revenue composition

# Global Reach Enables Reduction in Country Risk

Company's business is classified under 4 heads:

- North America/ US generics
- Europe/UK generics
- Australia and New Zealand
- Rest of the world (RoW) generics (CIS, Middle Eastern, African and South-East Asian countries)

REVENUE MIX



# The UK is the highest contributor to Marksans Pharma's revenues



Marksans Pharma Ltd.

**The UK**

**510.0**

Total revenues  
(₹ Cr.)

**23.5%**

Y-o-y growth

**45.0%**

Contribution to  
total revenues

## Overview of the market

- The UK pharmaceutical market is estimated to grow from ~USD 29 billion in 2015 to ~USD 43 billion by 2020, at a CAGR of 8.4%, driven primarily by a robust life sciences industry

## Company presence

- One of the top 5 Indian pharma companies in the UK
- UK business is driven by its two subsidiaries, Relonchem and Bell
- Bell has a strong OTC portfolio with 50+ products
- Relonchem's portfolio comprises high-end Rx portfolio of 100+ products

## Outlook

- Company has 50+ products in the pipeline in different stages to cater UK market
- Company is awaiting approval for ~20 MAs in the UK market

# Marksans is among a few Indian players with a proprietary marketing presence in the US



Marksans Pharma Ltd.

**The  
United  
States**

**436.4**

Total revenues  
(₹ Cr.)

**6.1%**

Y-o-y growth

**38.5%**

Contribution to  
total revenues

## Overview of the market

- The US holds over 30-40% of the global pharmaceutical market. It is expected to reach USD 190.4 billion by 2024, at a projected CAGR of 10.6% during 2019-2024, due to favoring government programs and policies

## Company presence

- In June 2015, Marksans acquired Time-Cap Labs which enabled Marksans to expand its offering in US market
- 30+ products, positioned in the niche soft gel category
- Proprietary marketing presence with 100% integration of Time-Cap Laboratories
- Strong distribution channel marketing for both OTC and Rx products

## Outlook

- Strengthen company's US operations in the coming years
- Add 4-5 new products to its portfolio during the year under review

# Australia and NZ region continue to deliver high teens growth in FY20



Marksans Pharma Ltd.

**Australia  
and New  
Zealand**

**140.7**

Total Revenues  
(₹ Cr.)

**17.3%**

Y-o-y growth

**12.4%**

Contribution to  
total revenues

## Overview of the market

- Australia's pharmaceutical market is set to rise from >\$22.85 billion in 2016 to \$25.2 billion by 2020 registering a CAGR of 2%

## Company presence

- Marksans carries out business operations in Australia and New Zealand through its subsidiary Nova Pharmaceuticals
- Nova is one of the leading generics and private label suppliers in Australia
- Tie-ups with topmost retailers & pharmacies in Australia, like Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings
- Presence in key therapeutic areas

## Outlook

- Australia and New Zealand will continue to remain focus markets for the Company

# After harnessing the regulated markets, Marksans is venturing out in the emerging countries



Marksans Pharma Ltd.

**Rest of  
the world**

**47.4**

Total Revenues  
(₹ Cr.)

**-21.3%**

Y-o-y growth

**4.2%**

Contribution to  
total revenues

## Overview of the markets

- ROW includes markets of South East Asia, MENA, Russian Federation & Africa

## Company presence

- Targeting four major clusters such as South East Asia, Russia and the CIS, Middle East and Africa
- In these four clusters, specific countries like Iraq, Kenya, Ukraine, Sri Lanka and Myanmar are targeted
- Started filing for approvals in these countries

## Outlook

- Company is strengthening its presence in the target markets and expects to generate 10% of the Company's revenue by FY22




# Investment Rationale



# Investment Rationale




Company is widening its products portfolio in the complex and high-margin generics segment



The US, the UK and Australia are the key Marksans' markets with all of them being now empowered with all regulatory approvals



Marksans is among a handful of Indian players with a proprietary marketing presence in the US which is world's largest pharma market



Marksans is among a few mid and small-sized pharma companies to have created an integrated business model by engaging R&D team in creating and filing dossiers across major markets



The new state-of-the-art R&D center in Navi Mumbai (Nerul) is focused on formulations and novel drug delivery systems



Company has repaid long-term loans, deleveraged the Balance Sheet and reinvested the surplus in R&D, capacity creation and brownfield expansion



Marksans Pharma Ltd.



# Marksans Pharma Ltd.

## Investor Relations Team at Marksans Pharma

Jitendra Sharma, CFO  
Marksans Pharma Ltd  
Tel: +91 022 40012000  
jitendra@marksanspharma.com

Dikshita Jain  
Christensen Investor Relations  
Tel : +91 22 4215 0210  
djain@christensenir.com

*Corporate Office:* 11th Floor Grandeur, Off Veera Desai Road,  
Opp Gundecha Symphony, Andheri (W), Mumbai 400 053. Maharashtra - India

**© 2020 Marksans Pharma Limited, All Rights Reserved.**

"Marksans Pharma" and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.